A new pyrrolopyrimidine alkaloid, rigidin E (1) and the known metabolites rigidin (2) and 1-methylherbipoline (3) have been isolated from a Papua New Guinea tunicate Eudistoma sp. A combination of spectroscopic data were used to determine the structures of these metabolites.
Introduction
Tunicates belonging to the genus Eudistoma have been the sources of numerous novel and bioactive secondary metabolites. β-Carboline alkaloids have been the predominant structure class isolated from this particular genus to date [1] [2] [3] [4] [5] , however macrolides [6] , indoles [7, 8] and aromatic polysulfides [9] have also been reported. In 1990 Kobayashi et al. reported the isolation of rigidin (2) from an Okinawan marine tunicate Eudistoma cf. rigida; this novel compound displayed calmodulin antagonistic activity and was the first pyrrolopyrimidine alkaloid to be isolated from a marine source [10] . More recently three new rigidin congeners, rigidins B-D (4-6) have been isolated from the tunicate Cystodytes sp. [11] . In our continuing search for unique secondary metabolites from marine tunicates [12, 13] , we investigated a previously undescribed tunicate Eudistoma sp. collected from Papua New Guinea. These chemical studies resulted in the isolation of a new pyrrolopyrimidine derivative, which we have named rigidin E (1) along with the known metabolites rigidin (2) and 1-methylherbipoline (3). Herein we describe the isolation, structure elucidation and cytotoxicity of compounds 1-3. 
Results and Discussion
A freeze-dried sample of the undescribed Eudistoma sp. [14] (family Polycitoridae) was sequentially extracted with DCM, MeOH and H 2 O. The MeOH extract was subjected to gel permeation chromatography using Sephadex LH-20 (MeOH) to yield 9 fractions. Fractions 4 and 5 were further purified by reversed-phase C 18 HPLC using 0.1% aqueous TFA and increasing amounts of MeOH to yield 1-methylherbipoline (3, 38.7 mg, 0.198 % dry wt). Fractions 8 and 9 were individually chromatographed by C 18 HPLC using a 0.1% aqueous TFA/MeOH gradient to afford the new metabolite rigidin E (1, 3.6 mg, 0.018 % dry wt) and rigidin (2, 2.0 mg, 0.010 % dry wt), respectively. The previously reported metabolites rigidin (2) and 1-methylherbipoline (3) were readily identified by comparison of their MS and NMR data with literature values [1, 10, 15] .
Rigidin E (1) 139.6 ppm) showed no HMBC correlations to either of the broad exchangeable protons at H-1 and H-7, a pyrrolopyrimidine system was clearly identified since compound 1 had essentially identical carbon chemical shifts compared to the known compound rigidin (2). Hence structure 1, the 3-methyl analog of rigidin, was assigned to rigidin E. All three compounds were tested for cytotoxicity against the p53 wildtype (p53
) and p53 deficient (p53 -/-) HCT 116 human colon carcinoma cell lines, while 1 and 2 were also tested in the A431 human epidermoid carcinoma cell line. Only minimal growth inhibition at 100 µg/mL was identified for all metabolites, hence no further biological evaluations were pursued (see Table 1 ). Interestingly, rigidins B-D (4-6) have recently been shown to exhibit moderate cytotoxocity against murine leukemia L1210 cells. Preliminary biological results showed that at 10 µg/mL, compounds 4-6 inhibited leukemia tumor cell growth by 40%, 40% and 20% respectively [11] .
Conclusions
We have isolated and spectroscopically characterized a new pyrrolopyrimidine alkaloid, which we have named rigidin E (1). The known metabolites rigidin (2) and 1-methylherbipoline (3) were also isolated during our chemical investigations of a Papua New Guinea tunicate Eudistoma sp. Vogelstein of Johns Hopkins University for generously donating the HCT 116 cell lines. 
Experimental

General
Animal Material
A specimen of the undescribed Eudistoma sp. [14] was collected during May of 2001 by SCUBA diving (-10 m) at Milne Bay (S 10° 14.278', E 150° 54.782'), Papua New Guinea, and kept frozen prior to freeze-drying and extraction. Taxonomic voucher specimen MZUSP15712 has been deposited at the Museu de Zoologia, Universidade Federal de São Paulo, São Paulo, Brazil.
Extraction and Isolation
The freeze-dried Eudistoma sp. (19.6 g) was sequentially extracted with DCM (2 × 400 mL), MeOH (2 × 400 mL) and H 2 O (2 × 400 mL). The MeOH extract (4.0 g) was subjected to gel permeation chromatography using a Sephadex LH-20 column with 100% MeOH as the eluant at a flowrate of 3.5 mL/min to yield 9 fractions. Fractions 4 and 5 (209.7 mg) were purified by semipreparative HPLC using a C 18 column with a gradient from 100% aqueous TFA (0.1%) to 100% MeOH in 20 min at flowrate of 4.0 mL/min, which afforded 1-methylherbipoline (3, 38.7mg, 0.198 % dry wt). Fraction 8 (11.0 mg) was purified by C 18 HPLC using a gradient from 100% aqueous TFA (0.1%) to 100% MeOH in 18 min at flowrate of 4.0 mL/min to yield rigidin E (1, 3.6 mg, 0.018 % dry wt). Fraction 9 (8.8 mg) was also purified by C 18 HPLC using 100% aqueous TFA (0.1%) to 100% MeOH in 20 min at flowrate of 4.0 mL/min which afforded pure rigidin (2, 2.0 mg, 0.010 % dry wt).
Spectral Data
Rigidin E (1): stable dark green film; UV (MeOH) λ max 276 (ε 7000), 362 (ε 4000); UV (MeOH/NaOH) λ max 244 (sh, ε 9000), 284 (ε 7000), 340 (ε 5000), 404 (ε 5000); IR ν max (NaCl) 3600-3000, 1690, 1590, 1440, 1380, 1260, 1200, 1160, 1030, 800, 730 cm -1 ; 1 H-NMR (400 MHz, DMSO- 1-Methylherbipoline (3): identified by comparison of spectroscopic data with literature values [1, 10, 15] .
Cells and Culture Conditions
All cell cultures were grown at 37 °C, 5% CO 2 and maximal humidity (by equilibration). All media reagents were purchased from Invitrogen Corporation (Carlsbad, CA [16] .
Cell Proliferation Assay
The ability of drug to inhibit cellular growth was determined using the MTT assay [16] . For the HCT 116 cell lines, 8000 cells per well were plated in 96-well plates in 200 µL of the appropriate media (see above) and the cells were allowed to grow overnight. Serial dilutions of drug were then added to wells in quadruplicate. Control wells were treated with vehicle (DMSO). After 72 h of incubation at 37 °C and 5% CO 2 , the media was removed and 100 µL fresh media was added along with 10 µL of 2.5 mg/mL aqueous 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT). The cells were then incubated for 4 h under the same conditions as above. The media was then removed and 100 µL DMSO added to each well. The amount of formazan resulting from MTT metabolism was measured by observing absorbance at 540 nm using a Labsystems Multiskan Plus plate reader. Using the absorbance in the vehicle treated lanes as 100% survival (1.00 fractional survival) the fractional survival of each treatment was observed. Because no growth inhibition was observed after most of the diluted treatments only the survival at 100 µg/mL is presented. The protocol using the A431 cells was essentially identical to the HCT 116 assays except that 16000 cell per well were initially plated and the cells were exposed to drug for 96 h. Both the HCT 116 and A431 cell lines responded typically when treated with laboratory standards. For example, the IC 50 of makaluvamine C towards HCT 116 cells was 0.37 µg/mL
